osimertinib,tepotinib
merck,astrazeneca
['insight2', 'nsclc', 'sclc', 'osimertinib', 'tepotinib']
the #oncoalerttoptweet #esmo22 day 3 tweet oncoalert colleague insight2
tepotinib + osimertinib for egfrm
nsclc with met amplification
(metamp) after progression on first-
line (1l) osimertinib: initial results orr 50% best, 
?? Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees ?? We are #OncoAlert ??